All In Biotech

Drug Trial Radar · NCT03602079

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies

Last checked: Nov 19, 2026Latest source record: Aug 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

49

Actual

Start

Jul 16, 2018

Primary completion

Jan 12, 2022

Study completion Jan 12, 2022

Sponsor

Lead sponsor
Klus Pharma Inc.Industry
Sponsor type
Industry
First posted
Jul 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard therapies. Patients will receive study drug as a single IV infusion. Cycles will continue until disease progression or unacceptable toxicity.

Conditions

  • HER2-positive Breast Cancer
  • HER2 Gene Mutation
  • HER-2 Gene Amplification
  • HER2 Positive Gastric Cancer
  • Salivary Gland Cancer
  • Salivary Gland Tumor
  • Salivary Gland Carcinoma
  • Salivary Gland Neoplasms
  • Lung Cancer
  • Colo-rectal Cancer
  • Rare Diseases
  • Solid Tumor
  • Recurrent Gastric Cancer
  • Recurrent Colon Cancer
  • Recurrent Breast Cancer
  • Head and Neck Cancer
  • Head and Neck Carcinoma
  • Bladder Cancer
  • Cervical Cancer
  • Liver Cancer
  • Bile Duct Cancer
  • Urologic Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Recurrent Prostate Cancer
  • Rectal Cancer
  • Recurrent Ovarian Carcinoma
  • Recurrent Renal Cell Cancer
  • Rectal Cancer Stage II
  • Rectal Cancer Stage I
  • Rectal Cancer Stage III
  • Skin Cancer
  • Mouth Cancer
  • Lip Cancer Stage I
  • Tongue Cancer
  • Breast Neoplasm Malignant Primary
  • Larynx Cancer
  • Tonsil Cancer
  • Palate Cancer
  • Mucoepidermoid Carcinoma
  • Primary Peritoneal Carcinoma
  • Mucinous Adenocarcinoma Gastric
  • Mucinous Breast Cancer Recurrent
  • Cholangiocarcinoma

Interventions

  • A166Drug

    A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: Maximum Tolerated DoseTime frame: Minimum of 21 days from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Florida Cancer Specialists & Research Institute

    Sarasota, Florida

  • Beth Israel Deaconess Medical Center Cancer Center

    Boston, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Clinical Research Alliance, Inc.

    Lake Success, New York

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • Providence Cancer Institute

    Portland, Oregon

  • Mary Crowley Cancer Research Centers - Medical City

    Dallas, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • South Texas Accelerated Research Therapeutics, LLC (START)

    San Antonio, Texas

  • Virginia Cancer Specialist

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.